6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of March 2013

Commission File Number: 001-31368

 

 

SANOFI

(Translation of registrant’s name into English)

 

 

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  x              Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨             No  x

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-            

 

 

 

In March 2013, Sanofi issued the press releases attached hereto as Exhibits 99.1 to 99.3 which are incorporated herein by reference.

Exhibit List

 

Exhibit

No.

   

Description

Exhibit 99.1    Press release dated March 8, 2013: Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Exhibit 99.2    Press release dated March 5, 2013: Composition of the Board of Directors of Sanofi
Exhibit 99.3    Press release dated March 2, 2013: Filing of the 2012 U.S. Form 20-F and French “Document de Référence” containing the Annual Financial Report

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: March 12, 2013

       SANOFI
    By  

/S/ John Felitti

    Name:   John Felitti
    Title:   Associate Vice President,
      Corporate Law, Financial & Securities Law

 

3

Exhibit Index

 

Exhibit

No.

   

Description

Exhibit 99.1    Press release dated March 8, 2013: Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Exhibit 99.2    Press release dated March 5, 2013: Composition of the Board of Directors of Sanofi
Exhibit 99.3    Press release dated March 2, 2013: Filing of the 2012 U.S. Form 20-F and French “Document de Référence” containing the Annual Financial Report

 

4